AzTrials
AzTrials

Liver CirrhosisNCT05672589

To Compare Relaxed Rotational Thromboelastometry Cut-offs With Standard Cut-offs for Guiding Blood Product Use Before Invasive Procedures in Cirrhosis and Acute on Chronic Liver Failure Patients

A study testing Relaxed Rotational Thromboelastometry and Standard Coagulation Tests in people with Liver Cirrhosis and Acute on Chronic Liver Failure, run by Institute of Liver and Biliary Sciences, India at 1 site in India.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Hypothesis Relaxed ROTEM cutoff guided blood product transfusion will result in less blood products use without increasing bleeding complications for invasive procedures in cirrhosis or acute on chronic liver failure (ACLF) patients AIM:- To evaluate the efficacy and safety of Relaxed threshold (as compared to… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Relaxed Rotational Thromboelastometry and Standard Coagulation Tests
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,050 participants
Where
1 siteIndia
Study dates
2 Feb 2023to 31 Dec 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All Cirrhosis and/or ACLF patients >18 yrs, scheduled to undergo an high risk invasive procedure with severe coagulopathy requiring correction as per risk category and degree of coagulopathy on conventional coagulation tests.

Who cannot join

  • Ongoing bleeding
  • Bleeding within last 3 days
  • ACLF patients going for LT may be added in exclusion criteria
  • Antiplatelet or anticoagulant therapy (discontinued <7 d before)
  • Hemodialysis in last 3 days

Trial locations and contacts

1 site in 1 country.

Dr Tushar Madke, MD contact

01146300000

drtusharmadke@gmail.com

India1 site, 1 recruiting
  • Institute of Liver & Biliary Sciences

    New Delhi, National Capital Territory of Delhi, 11070

    Dr Tushar Madke, MD, 01146300000, drtusharmadke@gmail.com

    Recruiting

Other trials in India

About this study

Official title: To Compare Relaxed Rotational Thromboelastometry Cut-offs With Standard Cut-offs for Guiding Blood Product Use Before Invasive Procedures in Cirrhosis and Acute on Chronic Liver Failure Patients: A Randomized Controlled Trial

Hypothesis

Relaxed ROTEM cutoff guided blood product transfusion will result in less blood products use without increasing bleeding complications for invasive procedures in cirrhosis or acute on chronic liver failure (ACLF) patients

Read more

AIM:- To evaluate the efficacy and safety of Relaxed threshold (as compared to conventional thresholds) for blood product transfusion for invasive procedures in cirrhosis or acute on chronic liver failure (ACLF) patients

Objective -

Primary objective:

To compare the reduction in amount of total component transfused (ml/kg) in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.

Secondary objectives:

To compare the amount of FFP (ml/kg) transfused in Relaxed Rotational Thromboelastometry cut off based versus Standard Rotational Thromboelastometry cut off based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.

To compare the amount of Platelet (ml/kg) transfused in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.

To compare the amount of cryoprecipitate (ml/kg) transfused in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.

To compare the bleeding rate in Relaxed Rotational Thromboelastometry cut off based versus Conventional Rotational Thromboelastometry cut off based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.

To compare the rate of transfusion reactions in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.

To compare the cost incurred in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.

Read the detailed description

Methodology

Investigator will be following guidelines given by Society of Interventional Radiology for any intervention for coagulopathy correction.

Different procedures which are routinely carry out at our institute will be divided into high risk vs low risk as per Society of Interventional Radiology

Low risk: Peripherally inserted central catheter placement, Paracentesis, Thoracocentesis, Central venous cannulation, Lumbar puncture, Dialysis catheter placement

Low risk: Solid organ biopsies, Transjugular intrahepatic portosystemic shunts, Biliary interventions (cholecystostomy tube placement)

If the patient has evidence of ongoing sepsis (Positive blood culture, increased procalcitonin, shock, fever etc) or renal dysfunction, then he will be considered to be at high risk for the procedure.

After determining the risk category of the procedure, patients will decide to receive coagulopathy correction based on CCT (Society of Interventional Radiology). Those patients who do not require correction will be excluded.

For high risk procedures: PLT < 20, INR >2.5, Fibrinogen < 100 mg/dL

For low risk procedures: PLT < 30, INR > 2.0, Fibrinogen < 100 mg/dL

Those patients who will require coagulopathy correction will be randomized to receive correction based on standard ROTEM criteria versus Relaxed ROTEM criteria.

Standard ROTEM criteria:

CT EX >80 s �' FFP/PCC(if volume overload)

MCF EX <35 mm

MCF FIB <8 mm �' Cryoprecipitate transfusion

MCF FIB ≥8 mm �' Platelets transfusion

Relaxed ROTEM criteria:

CT EX >90 s �' FFP/PCC(if volume overload)

MCF EX <30 mm

MCF FIB <7 mm �' Cryoprecipitate transfusion

MCF FIB ≥7 mm �' Platelets transfusion

CCTs and/or ROTEM will be revised 12 hourly for 24 hours, then every 24 hours for next 48 hours; and if bleeding complications occur. However patients will undergo a procedure immediately after the coagulopathy correction based on baseline CCT and/or ROTEM. Patients will be followed up till day 28 post procedure for procedure related bleeding and non bleeding complications.

Acute kidney injury:

The Kidney Disease Improving Global Outcomes (KDIGO) guidelines define AKI as any of the following:

  1. Increase in sCr by ≥0.3 mg/dl within 48 h or
  2. Increase in sCr to ≥1.5x baseline, which is known or presumed to have occurred within the prior 7 days or
  3. Urine volume <0.5 ml/kg/h for 6 h

Sepsis:

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.

● Organ dysfunction can be identified as an acute change in total SOFA score ≥2 points consequent to the infection

Study population: All Cirrhosis and/or ACLF patients >18 yrs, scheduled to undergo an high risk invasive procedure with severe coagulopathy requiring correction as per risk category and degree of coagulopathy on conventional coagulation tests.

Study design: Randomized controlled trial

Study period: 1 years

Sample size: 1050

Assuming that the proportion of patients requiring any blood products transfusion (i.e either FFP/platelets/ cryoprecipitate), in standard criteria group: 20% [Ref:Pietri etal. HEPATOLOGY 2016;63:566-573] and Relaxed group criteria: 13% (1/3rd decrease).

Two-sided significance level(1-alpha): 95

Power(1-beta, % chance of detecting): 80

Ratio of sample size, Unexposed/Exposed: 1

Percent of Unexposed with Outcome: 20

Percent of Exposed with Outcome: 13

Investigator decided to enroll total 1050 patients considering 10% dropout rate, 525 subjects in each arm

Patients were randomized to either Relaxed ROTEM or conventional ROTEM transfusion groups in a 1:1 ratio by random computer generated sequence

Monitoring and assessment: All the parameters of the objective and also noted any adverse effects.

Stopping rule: If patient decided to withdraw from study

Being tested
Relaxed Rotational Thromboelastometry, Standard Coagulation Tests
Medical subject headings
Liver Cirrhosis, Acute-On-Chronic Liver Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Relaxed Rotational ThromboelastometryDiagnostic test

    Relaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients. bleed.

  • Standard Coagulation TestsDiagnostic test

    Standard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed.

Study groups in NCT05672589
Study groupRoleWhat they receive
Relaxed rotational thromboelastometryExperimentalRelaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients bleed.
Receives: Diagnostic Test: Relaxed Rotational Thromboelastometry
Standard coagulation testsActive comparatorStandard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed
Receives: Diagnostic Test: Standard Coagulation Tests

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To compare the proportion of patients requiring any blood products transfusion (i.e FFP / platelets / cryoprecipitate)

    Measured: 0 hours

Secondary outcomes (10)
  1. To compare the proportion of patients requiring FFP transfusion

    Measured: 0 hours

  2. To compare the proportion of patients requiring platelets transfusion

    Measured: 0 hours

  3. To compare the proportion of patients requiring cryoprecipitate transfusion

    Measured: 0 hours

  4. To compare the proportion of patients requiring tranexamic acid infusion

    Measured: 0 hours

  5. To compare the amount of FFP transfused (mL) in patients requiring FFP transfusion per patient

    Measured: 0 hours

  6. To compare the amount of platelets transfused (SDAP units) in patients requiring platelet transfusion per patient

    Measured: 0 hours

  7. To compare the amount of cryoprecipitate transfused (units) in patients requiring cryoprecipitate transfusion per patient

    Measured: 0 hours

  8. To compare the occurrence of bleeding, defined as overt bleeding or hemoglobin drop requiring transfusion with a target of 8 g/dL 28 days patient survival

    Measured: 28 days

  9. To compare the transfusion-related side effects, defined as any side effect occurring within 6 hours of blood products infusion; and Procedure-related complications other than bleeding

    Measured: 6 hours

  10. To compare the cost incurred

    Measured: 0 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jan 2023
  2. Study start2 Feb 2023
  3. Primary completion31 Dec 2023 (estimated)
  4. Study completion31 Dec 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,050 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05672589
Sponsor's protocol ID
ILBS-Cirrhosis-51
Status last verified
Nov 2022
First submitted
3 Jan 2023
Last updated
18 Jun 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Relaxed Rotational Thromboelastometry and Standard Coagulation Tests in people with Liver Cirrhosis and Acute on Chronic Liver Failure, run by Institute of Liver and Biliary Sciences, India at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Dr Tushar Madke, MD (01146300000, drtusharmadke@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To compare the proportion of patients requiring any blood products transfusion (i.e FFP / platelets / cryoprecipitate) (time frame: 0 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in